(Q38920881)

7 September 2017

Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes (English)

1 reference

7 September 2017

Baisakhi Raychaudhuri

1

1 reference

7 September 2017

Patricia Rayman

2

1 reference

7 September 2017

Pengjing Huang

3

1 reference

7 September 2017

Matthew Grabowski

4

1 reference

7 September 2017

Dolores Hambardzumyan

5

1 reference

7 September 2017

James H Finke

6

1 reference

7 September 2017

Michael A Vogelbaum

7

1 reference

7 September 2017

13 January 2015

1 reference

Journal of Neuro-Oncology

7 September 2017

1 reference

7 September 2017

122

1 reference

7 September 2017

2

1 reference

7 September 2017

293-301

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-015-1720-6

7 September 2017

0 references

cites work

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Recent developments on immunotherapy for brain cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Therapeutic targeting of c-KIT in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Sunitinib in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Genetic modeling of gliomas in mice: new tools to tackle old problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Myeloid-derived suppressor cells: a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

The role of myeloid cells in the promotion of tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Continuous daily sunitinib for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1720-6

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

21 January 2018

1 reference

12 December 2020

Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway

1 reference

12 December 2020

Myeloid-derived suppressor cells

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

10.1007/S11060-015-1720-6

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference